Sector News

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

January 15, 2022
Life sciences

Through a spate of dealmaking over the past few years, Sanofi has made its intentions in the gene and cell therapy field clear. The company seems uninterested in hard-to-manufacture treatments that consist of individual patient cells genetically modified outside the body, instead favoring ones meant to be used “off the shelf.”

In 2020, for instance, the French drugmaker bought Kiadis Pharma, which is working on more convenient cell treatments for cancer. Sanofi acquired another off-the-shelf cell therapy developer, Tidal Therapeutics, the following year, and envisions its recent investments in messenger RNA technology as aiding in the effort.

In doing so, Sanofi isn’t just bypassing the first generation of so-called CAR-T therapies, which are powerful tools against certain blood cancers but are limited by their complexity. It’s also casting aside outside-the-body treatments for genetic diseases, a class that includes drugs from CRISPR Therapeutics and Bluebird bio that have shown considerable promise treating blood diseases like beta thalassemia and sickle cell. READ MORE

By Ben Fidler

Source: biopharmadive.com

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

JPM 2022: Galapagos execs troll for deals at J.P. Morgan but will hold off on signing for CEO-in-waiting

Life sciences

After dropping a late-stage asset and hitting an FDA roadblock in the JAK inhibitor class last year, Galapagos is in need of a 2022 rebound. With active discussions underway at the J.P. Morgan Healthcare Conference to find an acquisition target and a new CEO expected within weeks, the biopharma is trying to spark a revival.

Send this to a friend